This article maps the full arc: semaglutide, then Tirzepatide, then triple-active Retatrutide. It summarizes the 2023 NEJM data and walks through sourcing and protocol design for Canadian researchers. You will find the trial evidence, a clear comparison table, compliance steps, and a supplier checklist.
